Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202304626 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Yifan Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Pr…. Hauptthemen laut MEDLINE: Nanomedicine. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 394 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
As an indispensable part of the human sensory system, visual acuity may be impaired and even develop into irreversible blindness due to various ocular pathologies. Among ocular diseases, fundus neovascularization diseases (FNDs) are prominent etiologies of visual impairment worldwide. Intravitreal injection of anti‐vascular endothelial growth factor drugs remains the primary therapy but is hurdled by common complications and incomplete potency. To renovate the current therapeutic modalities, nanomedicine emerged as the times required, which is endowed with advanced capabilities, able to fulfill the effective ocular fundus drug delivery and achieve precise drug release control, thus further improving the therapeutic effect. This review provides a comprehensive summary of advances in nanomedicine for FND management from state‐of‐the‐art studies. First, the current therapeutic modalities for FNDs are thoroughly introduced, focusing on the key challenges of ocular fundus drug delivery. Second, nanocarriers are comprehensively reviewed for ocular posterior drug delivery based on the nanostructures: polymer‐based nanocarriers, lipid‐based nanocarriers, and inorganic nanoparticles. Thirdly, the characteristics of the fundus microenvironment, their pathological changes during FNDs, and corresponding strategies for constructing smart nanocarriers are elaborated. Furthermore, the challenges and prospects of nanomedicine for FND management are thoroughly discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincia…
ORCID-Profile: Yifan Zhou, Mingyu Xu, Wenyue Shen, Haijie Han, Juan Ye
Förderung
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhou, Y., Xu, M., Shen, W., Xu, Y., Shao, A., Xu, P., Yao, K., Han, H., & Ye, J. (2024). Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202304626
Vancouver
Zhou Y, Xu M, Shen W, Xu Y, Shao A, Xu P, et al. Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202304626
BibTeX
@article{Zhou2024,
author = {Zhou, Yifan and Xu, Mingyu and Shen, Wenyue and Xu, Yufeng and Shao, An and Xu, Peifang and Yao, Ke and Han, Haijie and Ye, Juan},
title = {Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202304626}
}
EUVIMED